Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26644935 | 1.00 | JAK3 (0.43) | JAK3CSNK1DCSNK1ELRRK2EGLN1 | |
| SCHEMBL30622341 | 0.92 | CSNK1D (0.46) | JAK3CSNK1DCSNK1ELRRK2LIMK1 | |
| SCHEMBL26644841 | 0.92 | CSNK1D (0.46) | JAK3CSNK1DCSNK1ELRRK2LIMK1 | |
| SCHEMBL30622345 | 0.90 | JAK3 (0.45) | JAK3LRRK2BTKLIMK1 | |
| SCHEMBL26644977 | 0.90 | JAK3 (0.45) | JAK3CSNK1DCSNK1EBTK | |
| SCHEMBL30622428 | 0.90 | JAK3 (0.45) | JAK3CSNK1DCSNK1EBTK | |
| SCHEMBL26644982 | 0.90 | JAK3 (0.45) | JAK3LRRK2BTKLIMK1 | |
| SCHEMBL30622424 | 0.88 | JAK3 (0.44) | JAK3BTKLIMK1LIMK2 | |
| SCHEMBL26644947 | 0.88 | JAK3 (0.44) | JAK3BTKLIMK1LIMK2 | |
| SCHEMBL30622385 | 0.87 | JAK3 (0.43) | JAK3CSNK1DCSNK1EBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | claimed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | claimed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |